CPRX vs. SNDX, AGIO, SDGR, GPCR, AMRX, SUPN, AVDL, HRMY, TARO, and PTGX
Should you be buying Catalyst Pharmaceuticals stock or one of its competitors? The main competitors of Catalyst Pharmaceuticals include Syndax Pharmaceuticals (SNDX), Agios Pharmaceuticals (AGIO), Schrödinger (SDGR), Structure Therapeutics (GPCR), Amneal Pharmaceuticals (AMRX), Supernus Pharmaceuticals (SUPN), Avadel Pharmaceuticals (AVDL), Harmony Biosciences (HRMY), Taro Pharmaceutical Industries (TARO), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical preparations" industry.
Syndax Pharmaceuticals (NASDAQ:SNDX) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, community ranking, profitability, risk and dividends.
Catalyst Pharmaceuticals received 118 more outperform votes than Syndax Pharmaceuticals when rated by MarketBeat users. Likewise, 74.38% of users gave Catalyst Pharmaceuticals an outperform vote while only 64.54% of users gave Syndax Pharmaceuticals an outperform vote.
In the previous week, Catalyst Pharmaceuticals had 1 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 6 mentions for Catalyst Pharmaceuticals and 5 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.52 beat Catalyst Pharmaceuticals' score of 0.47 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.
Syndax Pharmaceuticals has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.
Catalyst Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Catalyst Pharmaceuticals has a net margin of 17.93% compared to Catalyst Pharmaceuticals' net margin of 0.00%. Syndax Pharmaceuticals' return on equity of 26.56% beat Catalyst Pharmaceuticals' return on equity.
Syndax Pharmaceuticals currently has a consensus target price of $34.42, suggesting a potential upside of 54.61%. Catalyst Pharmaceuticals has a consensus target price of $26.43, suggesting a potential upside of 75.96%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Catalyst Pharmaceuticals is more favorable than Syndax Pharmaceuticals.
79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 11.0% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Catalyst Pharmaceuticals beats Syndax Pharmaceuticals on 15 of the 18 factors compared between the two stocks.
Get Catalyst Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Catalyst Pharmaceuticals Competitors List
Related Companies and Tools
